Taysha IPO Presentation Deck

Our strategy is focused on rapid clinical and commercial development We leverage a clinically and commercially proven capsid, manufacturing process, and delivery method Our strategy is designed to accelerate development timelines and increase the probability of success across our pipeline U TAYSHA BIGENE THERAPIES LU AAV9 vector for delivery of therapeutic transgene Demonstrated safety and efficacy across multiple CNS indications Intrathecal (IT) route of administration - Enables direct targeting to CNS Validated biodistribution and safety profile Proven HEK293 Suspension Process Highly scalable and excellent yields Access to GMP capacity at 500L scale, with total capacity up to 600L 10

View entire presentation